ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 388

Induction of Anti-Citrullinated Protein Antibodies By Peptidyl Arginine Deiminase Immunization: A New Model for the Development of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis

Fanny Arnoux1,2, Nathalie Lambert1,3, Nathalie Balandraud1,2,4, Jean Roudier1,3,5 and Isabelle Auger1,2, 1Aix Marseille University, Marseille, France, 2INSERM UMRs 1097, Marseille, France, 3Arthrites auto-immunes, INSERM UMRs 1097, Marseille, France, 4APHM, Marseille, France, 5Rheumatology dept, APHM, Marseille, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Animal Models Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The most important immunological event in rheumatoid arthritis (RA) is the development of anti-citrullinated protein autoantibodies (ACPAs). ACPAs are present in 2/3 of patients. The mechanisms leading to the production of ACPAs are unknown. ACPAs are produced in the absence of identified T cell responses specific for each citrullinated protein. Peptidyl arginine deiminase 4 (PAD4), which binds numerous proteins and citrullinates them is the target of autoantibodies in early RA. This suggests a model for the emergence of ACPAs in the absence T cells specific for each citrullinated antigen: anti-citrullinated protein autoantibodies could arise because PADs are recognized by T cells which help the production of autoantibodies to proteins being citrullinated by PADs, according to a “hapten/carrier” model. Here, we tested this model in mice.

Methods:

We used C3H mice which express a particular IEbk whose third hypervariable region is highly homologous to that of RA-associated HLA-DRB1*04:01 allele and DBA/2 mice whose IEbdis similar to that of non RA-associated HLA-DRB1*04:02. Mice were immunized subcutaneously with PADs or phosphate buffered saline (PBS) in Freund’s complete adjuvant (CFA). Three booster injections of PAD or PBS in Freund’ incomplete adjuvant (IFA) were given subcutaneously 15, 35 and 55 days later. Sera from primed mice were: 1) tested for anti-PAD antibodies by ELISA. 2) tested for T cell responses to native or citrullinated fibrinogen 65 days after PAD immunization. 3) tested for anti-citrullinated fibrinogen antibodies by ELISA using fibrinogen peptides under citrullinated and native form.

Results:

C3H mice immunized with human PAD2 or PAD4 developed antibodies and T cells to PADs and IgG antibodies to citrullinated peptides from fibrinogen, in the absence of T cell response to fibrinogen. To test whether the observed hapten carrier effect applies to immunization with self-proteins, we immunized C3H mice with murine PAD2 or PAD4 and looked for antibodies to peptides from fibrinogen under native or citrullinated form. The hapten carrier effect also occurred in the self-situation. Finally, to analyze the effect of the MHC background on hapten carrier immunization, we immunized DBA/2 mice whose IEbdis similar to that of non RA-associated HLA-DRB1*04:02. DBA/2 mice failed to develop antibodies to citrullinated fibrinogen peptides.

Conclusion:

T cell immunization to PAD proteins triggers ACPAs through a hapten carrier mechanism in which the carrier is PAD which performs citrullination and the hapten any protein being citrullinated by PAD.


Disclosure: F. Arnoux, None; N. Lambert, None; N. Balandraud, None; J. Roudier, None; I. Auger, None.

To cite this abstract in AMA style:

Arnoux F, Lambert N, Balandraud N, Roudier J, Auger I. Induction of Anti-Citrullinated Protein Antibodies By Peptidyl Arginine Deiminase Immunization: A New Model for the Development of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/induction-of-anti-citrullinated-protein-antibodies-by-peptidyl-arginine-deiminase-immunization-a-new-model-for-the-development-of-anti-citrullinated-protein-antibodies-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/induction-of-anti-citrullinated-protein-antibodies-by-peptidyl-arginine-deiminase-immunization-a-new-model-for-the-development-of-anti-citrullinated-protein-antibodies-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology